Brainomix
Develops AI-powered imaging tools for stroke and lung fibrosis
$6.8MSeries C+
Role not disclosedBI
Boehringer Ingelheim Venture Fund
Activity from announced rounds
Activity in this selectionAI
Boehringer Ingelheim Venture Fund is a corporate venture investment operation identified in Cloverleaf Bio and Brainomix financing histories.
Recorded funding activity
Cloverleaf develops engineered transfer-RNA therapies intended to inhibit cancer cells’ RNA-modifying enzymes. Brainomix develops AI imaging tools for stroke and lung fibrosis. The announcements connect the venture operation to both experimental therapeutics and clinical image analysis.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $6.8M 1 disclosed · full round size, not this investor’s share